{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:32:23Z","timestamp":1791844343953,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.anndiagpath.2021.151882","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T11:26:41Z","timestamp":1640258801000},"page":"151882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases"],"prefix":"10.1016","volume":"57","author":[{"given":"Li","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1033-7550","authenticated-orcid":false,"given":"Hongjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1513-8104","authenticated-orcid":false,"given":"Pancras C.W.","family":"Hogendoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8182-7082","authenticated-orcid":false,"given":"Hong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.anndiagpath.2021.151882_bb0005","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1359\/jbmr.080905","article-title":"CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone","volume":"24","author":"Forsyth","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.anndiagpath.2021.151882_bb0010","series-title":"WHO Classification of Tumours of Soft Tissue and Bone. Giant Cell Tumour of Bone","first-page":"4","volume":"Vol 4th","author":"Athanasou","year":"2013"},{"issue":"8","key":"10.1016\/j.anndiagpath.2021.151882_bb0015","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/jcp.2011.090852","article-title":"The immunophenotype of osteoclasts and macrophage polykaryons","volume":"64","author":"Maggiani","year":"2011","journal-title":"J Clin Pathol"},{"issue":"20","key":"10.1016\/j.anndiagpath.2021.151882_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205119","article-title":"Cell biology of Giant cell tumour of bone: crosstalk between m\/wt nucleosome H3.3, telomeres and osteoclastogenesis","volume":"13","author":"Forsyth","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.anndiagpath.2021.151882_bb0025","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2021.151882_bb0030","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.3892\/ol.2016.5246","article-title":"Denosumab treatment of inoperable or locally advanced giant cell tumor of bone","volume":"12","author":"Borkowska","year":"2016","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.anndiagpath.2021.151882_bb0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/PAS.0000000000000506","article-title":"Denosumab-treated Giant cell tumor of bone exhibits morphologic overlap with malignant Giant cell tumor of bone","volume":"40","author":"Wojcik","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151882_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.01.006","article-title":"Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone","volume":"59","author":"Traub","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.anndiagpath.2021.151882_bb0045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/jclinpath-2015-203248","article-title":"Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series","volume":"69","author":"Girolami","year":"2016","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2021.151882_bb0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/17453674.2014.1002345","article-title":"Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report","volume":"86","author":"van der Heijden","year":"2015","journal-title":"Acta Orthop"},{"issue":"16","key":"10.1016\/j.anndiagpath.2021.151882_bb0055","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","article-title":"Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone","volume":"18","author":"Branstetter","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2021.151882_bb0060","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2017.01.028","article-title":"Denosumab in advanced\/unresectable giant-cell tumour of bone (GCTB): for how long?","volume":"76","author":"Palmerini","year":"2017","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.anndiagpath.2021.151882_bb0065","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s00264-017-3536-9","article-title":"How safe and effective is denosumab for bone giant cell tumour?","volume":"41","author":"Errani","year":"2017","journal-title":"Int Orthop"},{"key":"10.1016\/j.anndiagpath.2021.151882_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2020.151479","article-title":"Spectrum of histological features of denosumab treated giant cell tumor of bone; potential pitfalls and diagnostic challenges for pathologists","volume":"45","author":"Tariq","year":"2020","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2021.151882_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PAS.0000000000001388","article-title":"Denosumab-treated Giant cell tumors of bone: a clinicopathologic analysis of 35 cases from the french Group of Bone Pathology","volume":"44","author":"Treffel","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151882_bb0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.humpath.2017.02.008","article-title":"Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls","volume":"63","author":"Roitman","year":"2017","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2021.151882_bb0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12253-016-0123-0","article-title":"Clinicopathological features of a series of 27 cases of post-denosumab treated Giant cell tumors of bones: a single institutional experience at a tertiary cancer referral Centre","volume":"23","author":"Rekhi","year":"2017","journal-title":"India. Pathol Oncol Res"},{"issue":"4","key":"10.1016\/j.anndiagpath.2021.151882_bb0090","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5114\/pjp.2016.65873","article-title":"Morphologic evaluation of the effect of denosumab on giant cell tumors of bone and a new grading scheme","volume":"67","author":"Erdogan","year":"2016","journal-title":"Pol J Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2021.151882_bb0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/PAS.0000000000001555","article-title":"Immunohistochemical characterization of Giant cell tumor of bone treated with denosumab: support for osteoblastic differentiation","volume":"45","author":"Kerr","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2021.151882_bb0100","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/his.13448","article-title":"Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses","volume":"72","author":"Kato","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2021.151882_bb0105","article-title":"Clinical and pathological analysis of giant cell tumor of bone with denosumab treatment and local recurrence","volume":"23","author":"Hayashida","year":"2020","journal-title":"J Orthop Sci"},{"issue":"8","key":"10.1016\/j.anndiagpath.2021.151882_bb0110","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1177\/1066896920920716","article-title":"Histomorphometric analysis of pre- and post-denosumab-treated Giant cell tumor of bone","volume":"28","author":"Ud Din","year":"2020","journal-title":"Int J Surg Pathol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2021.151882_bb0115","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/1066896916629546","article-title":"Giant cell tumor of bone with pseudosarcomatous changes leading to premature denosumab therapy interruption: a case report with review of the literature","volume":"24","author":"Sanchez-Pareja","year":"2016","journal-title":"Int J Surg Pathol"},{"issue":"5","key":"10.1016\/j.anndiagpath.2021.151882_bb0120","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/path.2301","article-title":"Telomere biology in giant cell tumour of bone","volume":"214","author":"Forsyth","year":"2008","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2021.151882_bb0125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/path.2500","article-title":"Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms","volume":"217","author":"De Boeck","year":"2009","journal-title":"J Pathol"},{"issue":"12","key":"10.1016\/j.anndiagpath.2021.151882_bb0130","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/ng.2814","article-title":"Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone","volume":"45","author":"Behjati","year":"2013","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.anndiagpath.2021.151882_bb0135","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1097\/PAS.0000000000000512","article-title":"Mutation analysis of H3F3A and H3F3B as a diagnostic tool for Giant cell tumor of bone and chondroblastoma","volume":"39","author":"Cleven","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2021.151882_bb0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/his.13190","article-title":"H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant","volume":"71","author":"L\u00fcke","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2021.151882_bb0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.humpath.2017.11.020","article-title":"Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone","volume":"73","author":"Yamamoto","year":"2018","journal-title":"Hum Pathol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2021.151882_bb0150","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/cncy.22000","article-title":"Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy","volume":"126","author":"Schaefer","year":"2018","journal-title":"Cancer Cytopathol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2021.151882_bb0155","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/PAS.0000000000000859","article-title":"H3F3A (Histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone","volume":"41","author":"Amary","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.anndiagpath.2021.151882_bb0160","first-page":"1230","article-title":"Factors of local recurrence of giant cell tumor of long bone after treatment: plain radiographs, pathology and surgical procedures","volume":"94","author":"Chanchairujira","year":"2011","journal-title":"J Med Assoc Thai"},{"issue":"2","key":"10.1016\/j.anndiagpath.2021.151882_bb0165","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00000421-199504000-00010","article-title":"Prolonged disease-free survival following surgical debulking and high-dose cisplatin\/doxorubicin in a patient with bulky metastases from giant cell tumor of bone refractory to \"standard\" chemotherapy","volume":"18","author":"Stewart","year":"1995","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2021.151882_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.prp.2017.10.023","article-title":"Detection of H3F3A p. G35W and p.G35R in giant cell tumor of bone by allele specific locked nucleic acid quantitative PCR (ASLNAqPCR)","volume":"214","author":"Gamberi","year":"2018","journal-title":"Pathol Res Pract"},{"issue":"2","key":"10.1016\/j.anndiagpath.2021.151882_bb0175","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/PAS.0000000000001571","article-title":"Correlation between immunohistochemistry and sequencing in H3G34-mutant gliomas","volume":"45","author":"Gianno","year":"2021","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.anndiagpath.2021.151882_bb0180","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00428-012-1235-x","article-title":"Smooth muscle actin expression in primary bone tumours","volume":"460","author":"Hemingway","year":"2012","journal-title":"Virchows Arch"},{"issue":"8","key":"10.1016\/j.anndiagpath.2021.151882_bb0185","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.anndiagpath.2021.151882_bb0190","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.2217\/fon-2019-0170","article-title":"Excess of second tumors in denosumab-treated patients: a metabolic hypothesis","volume":"15","author":"Tovazzi","year":"2019","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.anndiagpath.2021.151882_bb0195","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s11999-015-4249-2","article-title":"A high-grade sarcoma arising in a patient with recurrent benign Giant cell tumor of the proximal tibia while receiving treatment with denosumab","volume":"473","author":"Aponte-Tinao","year":"2015","journal-title":"Clin Orthop Relat Res"},{"issue":"11","key":"10.1016\/j.anndiagpath.2021.151882_bb0200","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/jjco\/hyx112","article-title":"Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab","volume":"47","author":"Tsukamoto","year":"2017","journal-title":"Jpn J Clin Oncol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913421001829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913421001829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:34:04Z","timestamp":1761078844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913421001829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":40,"alternative-id":["S1092913421001829"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2021.151882","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2021.151882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151882"}}